Physician profile
Faheem Abbasi
NPI 1710047295
$363.62
in general payments reported to CMS, 2019-2025
12 companies · $67.48 in 2025
The $67.48 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2020: $74.17 · 2021: $43.52 · 2022: $50.43 · 2023: $23.02 · 2025: $67.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $90.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $90.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $93.48 | 2021-2025 | Durolane |
| Si-Bone, INC. | $45.43 | 2019-2020 | |
| Fidia Pharma USA INC. | $40.93 | 2019-2020 | |
| Depuy Synthes Sales INC. | $38.57 | 2025 | Monovisc, Orthovisc |
| Electromed, INC. | $29.38 | 2022 | |
| Scilex Pharmaceuticals INC. | $28.71 | 2019 | |
| Horizon Therapeutics Plc | $25.62 | 2020 | |
| Avanos Medical | $16.77 | 2023 | Genvisc 850 Sodium Hyaluronate |
| Pfizer INC. | $13.95 | 2019 | |
| Assertio Therapeutics, INC. | $13.24 | 2020 | |
| Kaleo, INC. | $11.29 | 2019 | |
| Electronic Waveform Lab, INC. | $6.25 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faheem Abbasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.